The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Opdivo + Yervoy demonstrate durable survival benefit vs. chemotherapy in mesothelioma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a significant improvement in overall survival in patients with previously untreated, unresectable malignant pleural mesothelioma in the phase III CheckMate -743 clinical trial.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account